

## DAFTAR PUSTAKA

- Abera, Julian S., 2015. Incidence of Antituberculosis Drug Induced Hepatotoxicity and Associated Risk Factor Among Tuberculosis Patients in Dawro Zone, South Ethiopia: A Cohort Study.
- Abera W, Cheneke W, Abebe G. Incidence of antituberculosis drug induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study. *Int J Mycobacteriology*. 2016;5(1):14–20
- Ali A, Belachew T, Yami A, Ayen W. *Anti-Tuberculosis Drug Induced Hepatotoxicity among TB / HIV Co-Infected Patients at Jimma University Hospital, Ethiopia: Nested Case-Control Study*. *PloS One*. 2013;8(5):1–8.
- Anand, Anil C., & Hospitals, Indraprastha Apollo. (2015). Risk Factors of Hepatotoxicity During Anti-tuberculosis. *Medical Journal Armed Forces India*. (February), 45–49.
- Amanda, G. 2018. Peran Aerosol M. tuberculosis pada Penyebaran Infeksi Tuberkulosis. *Cerminan Dunia Kedokteran*, 63-65.
- Amiruddin, Ridwan. 2006. Faktor Resiko Kegagalan Konversi Pada Penderita TB Paru BTA Positif di Kota Ambon Tahun 2006. *Dinas kesehatan Kota Ambon*.
- Badie, BM, M. 2012. Comparing Radiological Features of Pulmonary Tuberculosis with and without HIV Infection. *Jurnal AIDS Clinic Res*, 3 (10), 1-3.

- Bang, E. 2009. Tuberkulosis, [https / medicine / medscape.com / article](https://medicine.medscape.com/article), diakses tanggal 05 Desember 2020.
- Bayupurnama, Putut. 2006. Hepatoksitas karena Obat dalam Buku Ajar Ilmu. Jakarta : Balai Penerbit FK UI.
- Borzakova, S.N.dkk. 2013. Viral and Drug-Induced Liver Damage in Children with Tuberculosis: Prevalence, Clinical Features. *Eksp Klin Gastroenterol*, 1: 38-43.
- Bustan, M.N. 2007. Epidemiologi Penyakit Tidak Menular. Edisi II. Jakarta: Rineka Cipta.
- Castrighini., Carolina., de.C.C.; Renata,K.R.; Neves., S.A.L.;Galvao., G.T.M., and Elucir,G. Crofton & John, (2000). Tuberkulosis Kinik, Widya Medika, Jakarta (2013). Epidemiological Profile of HIV/Tuberculosis Co-infection in a City the State of Sao Paulo Brazil. Volume 5, hal 119-122.
- Crofton & John, (2000). Tuberkulosis Kinik, Widya Medika, Jakarta.
- Dwisarwa S & Nurlaela, (2011). Merokok dan Tuberkulosis Paru (Studi Kasus do RS Margono Soekardjo Purwokerto)
- Danusantoso, H. 2012, Buku Saku Ilmu Penyakit Paru, Hipokrates, Jakarta.
- Depkes, RI., 2011. TBC Masalah Kesehatan Dunia. Jakarta: BPPSDMK
- Desy,2012. *Risk Factor of Tuberculosis Coinfection In Hiv/Aids Patient In Dr. Kariadi Hospital Semarang*.Faculty of Medicine Diponegoro University.

- Dessy, et.,all. 2012. *Analisis Kejadian Efek Samping Obat Pada Pasien Tb/Hiv Ko-Infeksi Di Rumah Sakitumum Persahabatan Jakarta. Jurnal ilmiah indonesia*.Vol. 6, No. 1, Januari 2021.
- Devarbhavi, Harshad. (2012). An update on drug-induced liver injury. *Journal of Clinical and Experimental Hepatology*, 2(3), 247–259
- Devarbhavi, Antituberculous drug-induced liver injury: Current perspective, *Trop. Gastroenterol.* 32 (2011) 167–174
- Dienstag, LJ, Isselbacher KJ. 2008. Toxic and drug induced hepatitis. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. *Harrison's Principles of Internal Medicine*. United States of America: McGraw Hill Company, 49-54.
- Dipiro, J.T., et al. 2005. *Pharmacotherapy Handbook*. Sixth edition. The Mc.Graw Hill. Company. USA. hal. 1891-1939.
- Essig, M. G. 2008. Alanine Aminotransferase, [http: www.webmd.com](http://www.webmd.com), diakses tanggal 05 Desember 2020.
- Getahun, H, et al, 2010. HIV Infection-Association Tuberculosis: The Epidemiology and the Response. *Clinical Infectious Diseases*, 50, S201-S207 <http://dx.doi.org/10.1086/651492>.
- Gunawan, Sulistia Gan dkk. 2011. *Farmakologi dan Terapi Edisi 5*. Jakarta: Departemen Farmakologi dan Terapeutik Fakultas Kedokteran Universitas Indonesia.
- Helmia dan lulu manase, 2004. *Tuberkulosis In alsagaff hood*, (Eds), Buku ajar ilmu penyakit paru: Surabaya.

<https://www.rsudaws.co.id/uploads/DOWNLOAD/Profil%20RSUD%20AW>

S%202017. Profil rumah sakit,2017.

Irianti, Dr. Rer. Net. T, Kuswandi, Yasin, Dr. N. M, Kusumaningtyas, R. A.

2016. Mengenal Anti-Tuberkulosis: Yogyakarta

Iskandar. Hubungan karakteristik penderita, lingkungan fisik, rumah dan

wilayah dengan kejadian tuberkulosis paru di Kabupaten Aceh

Tenggara tahun 2009 (tesis). Medan: Fakultas Kesehatan

Masyarakat Universitas Sumatera Utara; 2009.

Jasmer,R.M., et.,al. 2002. Short-Course Rifampin and Pyrazinamide

Company Latent Tuberculosis Infection: *A Multicenter Clinical Trial.*

*Annals. of. Int Med*, 137: 640.

Javadi, G. Shalviri, K. Gholami, et al, Adverse reactions of antituberculosis

drugs in hospitalized patients: incidence, severity, and risk factors,

*Pharmacoepidemiol, Drug Saf.* 16 (2007) 1104–1110.

Jessica raphaela., dkk. 2019. *Prevalensi dan Gambaran Umum*

*Drug-Induced Liver Injury Akibat Obat Anti Tuberkulosis pada*

*Pasien Tuberkulosis RSUP Sanglah Denpasar Periode Agustus*

*2016 –Juli 2017* Jurnal medika Udayana: Vol.8 No.9.

Kar P. 2012. Tuberculosis and Liver Disease: *management issues.*

*Tropical Gastroenterology*, 6(4):102-106.

Kato, H. et al. 2013. Risk factors for liver injury with an elevated serum

bilirubin concentration caused by antituberculous drugs, nternal

medicine. *The Japanese Society of Internal Medicine*, 52(19), pp.

2209–2214.

- Kementerian Kesehatan Republik Indonesia, 2014. Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan. *Pedoman nasional pengendalian tuberculosis.*
- Kementerian Kesehatan Republik Indonesia, 2015. Rencana Strategis Kementerian Kesehatan Tahun 2015-2019, Jakarta: Indonesia.
- Kemenkes RI, 2016. Tuberkulosis Temukan Obati Sampai Sembuh. Jakarta: Pusat Data dan Informasi Kementrian RI.
- Kisembo HN, et.al., 2012. Chest radiographic dinding of pulmonary tuberculosis Ni severely immunocompromised patients Alt human immunodeficiency virus. *The British Journal of Radiology*, June130-40
- Koda – Kimble, M.A., and Young, L.Y., 2005. Tuberculosis, in Applied Therapeutics. *The clinical drugs*, Seventh Ed., Lippincot Williams and Wilkens: Philadelphia.
- Kosasih, E. N. and Kosasih, A. S, 2008. Tafsiran hasil pemeriksaan laboratorium klinik. *Medical Laboratory Technology: Tangerang* 3(2), pp. 42–46.
- Kurniawati, E., 2013. Aplikasi Teori Health Belief Model Dalam Pencegahan Keputihan Patologis. *Jurnal Promkes*, Vol. 2, No. 2 Desember 2014: 117–127.
- Kumar pramod avti., dkk. Smokeless tobacco impairs the antioxidant denese in liver, lung and kidney of rats.Oxford. 2005.

- Latief M, Dar WR, Sofi N, Dar IA, Kasana B, Hussain M, dkk. Novel risk factors and early detection of anti-tubercular treatment induced liver injury. *Indian J Tuberc.* 2017;64(1):26-32.
- Lee, Schiodt FV. 2003. Drug induced liver disease. In: Yamada T, editor. *Textbook of Gastroenterology*. 4th ed. Philadelphia: Lippincott Williams & Wilkins, p.2352-65.
- Lee, A., dkk., 2005, Novel Mutations in *ndh* in Isoniazid Resistant Mycobacterium Tuberculosis Isolates, *Antimicrob Agents Chemother*, 45 (9), 2157.
- Luthariana, Lies., 2017. Faktor Risiko Terjadinya Hepatotoksisitas Imbas Obat Anti tuberkulosis pada Pasien HIV/AIDS. *Jurnal Penyakit Dalam Indonesia*. Vol 4: 23-24.
- Loubser, Shayne et al. 2010. Tuberculosis Drugs-First Line. <http://immunopaedia.org/index.php?id=260&L=0&key=0>. Diakses Desember 2020.
- Maulidya YN, Redjeki ES, Fanani E. 2017. Faktor Yang Mempengaruhi Keberhasilan Pengobatan Tuberkulosis (TB) Paru Pada Pasien Pasca Pengobatan Di Puskesmas Dinoyo Kota Malang. *Jurnal Preventia*, hal.2
- Maria de Fátima et.,all. 2012 Hepatotoxicity induced by antituberculosis drugs among patients coinfectd with HIV and tuberculosis Hospital das Clínicas de Pernambuco, Recife, Brasil. *Cad. Saúde Pública*, Rio de Janeiro, 28(4):698-708,

- Marzuki OA, Fauzi AR, Ayoub S, dkk. Prevalence and risk factors of anti-tuberculous drug induced hepatitis in Malaysia. *Singapore Med J.* 2008;49(9):688–693.
- Makonnen, daniel., 2015. TB/HIV co-infections and associated factors among patients on directly observed treatment short course in Northeastern Ethiopia: a 4 years retrospective study. Department of Medical Microbiology, Immunology and Parasitology, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia : *BMC Res Notes (2015) 8:666*
- Mulyadi. 2011. Profil Penderita Tuberculosis Paru di Pesisir Pantai Aceh Barat Daya (Kajian di Puskesmas Blangpidie). *J Respir Indo.*
- Nuraini, agustin., 2016. Analisis faktor klinik dan pengobatan yang mempengaruhi keberhasilan terapi Tuberkulosis pada pasien koinfeksi HIV–TB di klinik VCT RSD dr. Soebandi Jember, Farmasi, Universitas : Jember.
- Naga, S. Ilmi Penyakit Dalam. Yogyakarta : Diva Press: 2012.
- Natalie, Josephine, Kholis, Fathur Nur, & Ngestiningsih, Dwi. (2016). Jenis–Jenis Efek Samping Pengobatan Oat Dan Art Pada Pasien Dengan Koinfeksi Tb /Hiv Di Rsup Dr. Kariadi. 5(4), 1134–1145.
- Ningrum, Vitarani D. A., Megasari, Arnia., Hanifah, Suci., 2010. Hepatotoksisitas pada Pengobatan Tuberkulosis di RSUD Tangerang-Indonesia. *Jurnal Ilmiah Farmasi.*
- Notoatmodjo, S. 2012. Metodologi Penelitian Kesehatan. Jakarta: Rineka Cipta.

- Notoatmodjo., 2010, Metode Penelitian Kesehatan, Rineke Cipta, Jakarta.
- Noor, N. Epidemiologi. Jakarta: Rineka Cipta; 2008.
- Panjaitan F. Karakteristik Penderita Tuberkulosis Paru Dewasa rawat Inap di Rumah Sakit Umum dr. Soedarso Pontianak Periode September-November 2010. Fakultas Kedokteran Universitas Tanjungpura. 2012. (Skripsi).
- Pukenyte E, et al. 2007. Incidence of and risk factors for severe liver toxicity in HIVinfected patients in anti-tuberculosis treatment. *Int J Tuberc Lung Dis*, 11(1):78-84.
- Pratiwi, elsa,P., 2018. Efek Samping Obat Antituberkulosis Kategori I dan II Pasien Tuberkolosis Paru Dewasa di Rumah Sakit Hasan Sadikin.Bandung,Universitas Kedokteran Padjajaran.
- Rahayu, Ani. (2018). *Analisis Efektifitas Biaya Terapi Anti hipertensi Kombinasi Pada Pasien Hipertensi Di Ruang Rawat Inap RSUD DR. Soekardjo Tasikmalaya*. STIKes BTH Tasikmalaya.
- R. Shakya, BS Rao, B. Shrestha, Evaluasi faktor risiko untuk hepatotoksisitas yang diinduksi obat antituberkulosis pada populasi Nepal, Kathmandu Univ. Med. J.2 (2006) 2–4.
- Rahmawati F, R. Handayani, V. Gosal, Kajian Retrospektif Interaksi Obat di Rumah Sakit Pendidikan Dr. Sardjito Yogyakarta, *Majalah Farmasi Indonesia*, 2006;17(4):177-83.
- Rafiq S, Iqbal T, Jamil A, Khan HF. Pharmacokinetic studies of indoprofen in healthy volunteers and in patients. *International Journal of Agriculture & Biology*.2015.



- Ramappa V, Aithal GP. Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. *J Clin Exp Hepatol.* 2013;3(1):37–49.
- Resky hevia., L.2017. *Gambaran Kadar Enzim Transaminase Pada Pasien Tuberkulosis Yang Mendapat Terapi Obat Anti Tuberkulosis Di Unit Pengobatan Penyakit Paru-Paru Provinsi Kalimantan Barat.* Pendidikan Dokter, Fakultas Kedokteran, Universitas Tanjungpura, Pontianak, Kalimantan Barat.
- Rian, 2010. Pengaruh Efek Samping Obat Anti Tuberkulosis Terhadap Kejadian Default di Rumah Sakit Islam Pondok Kopi Jakarta Timur Januari 2008 – Mei 2010. Tesis, Dipublikasikan, Jakarta, Universitas Indonesia.
- Sacher RA, McPherson RA. 2004. Uji Fungsi Hati. Tinjauan Klinis Hasil Pemeriksaan Laboratorium, Edisi ke-11, Jakarta: Penerbit Buku Kedokteran EGC.
- Saukkonen JJ, et al. 2006. An official ATS statement: hepatotoxicity of antituberculosis therapy. *American Journal of Respiratory and Critical Care Medicine*, vol. 174.
- Saputri, A.S.A.R. 2015. Faktor-Faktor Koinfeksi TB Paru pada Pasien HIV/AIDS di Balai Kesehatan Paru Masyarakat (BKPM) Semarang Tahun 2015. Skripsi. Universitas Negeri Semarang.
- Sakamoto, K. 2012. The Pathology of Mycobacterium tuberculosis Infection. *Journal of Veterinary Pathology*, 49 (3): 423, diunduh 18 Desember 2020.

- Samuel Pola Karta Sembiring, Indonesia bebas tuberkulosis.2019. suka bumi: Jawa barat Hal.111
- Savita Mishra, Vidhu Aeri and Deepshikha Pande Katare. (2014). Hepatoprotektor protective Medication for Liver Injury. *World Journal and Pharmaceutical Sciences*, 5(3), 891–932.
- Sharifzadeh, M. Rasoulinejad, F. Valipour, et al, Evaluation of patient-related factors associated with causality, preventability, predictability, and severity of hepatotoxicity during antituberculosis treatment, *Pharmacol. Res.* 51 (2005) 353–358.
- Sherlock, S. & Dooley, J., 2002, *Diseases of the Liver and Biliary System*. Edisi ke 11. London: Blackwell Publishing
- Singla R., Khan N., Al-Sharif N., Ai-Sayegh M.O., Shaikh M.A., Osman M.M. 2010. Influence of diabetes on manifestations and treatment outcome of pulmonary TB patients. *Int J Tuberc Lung Dis.* 10: 74-79.
- Sudarsono, 2002. Penatalaksanaan tuberkulosis paru dalam strategis DOTS in palilingan J.F., (eds), *global management of tuberculosis reach an Indonesian Health for all in the year 2010*: Surabaya.
- Soo Hui L, Lee Cheng H, Loong Hui T, Mohamad N, Yazid A, Lay Harn G. Antituberculosis. *Webmed Central Pharmaceutical Sciences*.2011.
- Taha M, 2011. Risk factors of active tuberculosis in people living with HIV/AIDS in Southwest Ethiopia: A case control study.

- Toastmann et al. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. *Journal of Gastroenterology and Hepatology*. 2007; 10:192-202
- Wannamethee, 2001. *Smoking as a Modifiable Risk Factor for Type 2 Diabetes in Middle-Aged Men*, *Psychosocial Research*. Volume 24, Number 9
- WHO, 2015. Tuberculosis control in the southeast asia region: annual report 2015 Geneva: *World Health Organization*.
- World Health Organization (WHO), 2015. Global Tuberculosis Report. Geneva: WHO.
- Wijaya, A. S., & Putri, Y. M. 2013. KMB 1 Keperawatan Medikal Bedah Keperawatan Dewasa Teori Dan Contoh Askep. Yogyakarta: Nuha Medika.
- Wong, R. J. et al. 2007. Neonatal Jaundice: Bilirubin Physiology and Clinical Chemistry The online version of this article, along with updated information and services, is located on the World Wide Web at, doi: 10.1542/neo.8-2-e.
- Zelege,Abebe,Drug-inducedhepatotoxicity among TB/ HIV co-infected patients in a referral hospital, Ethiopia : Department of Pharmacy.Wollo University.2020: 13(2).